Literature DB >> 8256584

Stabilization of c-myc protein in human glioma cells.

H Shindo1, E Tani, T Matsumuto, T Hashimoto, J Furuyama.   

Abstract

The regulation of c-myc protein, product of c-myc/genes, was studied in four glioma cell lines by Northern blot, pulse-chase dot blot, immunoblot and immunoprecipitation analyses. Northern blot analysis revealed no overexpression of c-myc transcript, and pulse-chase dot blot analysis showed normal turnover rate of c-myc transcript, suggestive of no evidence of aberrant regulation of c-myc at post-transcriptional level. The synthesis levels of c-myc protein were shown by immunoprecipitation and closely associated with the c-myc transcript levels demonstrated by Northern blot, suggestive of no evidence of aberrant translational control of c-myc, whereas they were dissociated from the accumulation levels of c-myc protein shown by immunoblot, suggestive of an evidence of aberrant regulation of c-myc at post-translational level. The mean (+/- standard deviation) half-lives of c-myc protein in four glioma cell lines were calculated from the pulse-chase immunoprecipitation analysis, and being 98 +/- 8 to 143 +/- 11 min, were about four- to sixfold longer than normal. In surgical specimens, the immunostain of c-myc protein was not found in normal astrocytes but localized heterogenously in nuclei of reactive astrocytes and glioma cells, and increased in stained cell number in proportion to malignancy. Although this study was limited to four glioma cell lines, it suggests that the c-myc protein in glioma cells may be accumulated due to its prolonged half-life contributing to an uncontrolled proliferation.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8256584     DOI: 10.1007/bf00369446

Source DB:  PubMed          Journal:  Acta Neuropathol        ISSN: 0001-6322            Impact factor:   17.088


  45 in total

1.  Cleavage of structural proteins during the assembly of the head of bacteriophage T4.

Authors:  U K Laemmli
Journal:  Nature       Date:  1970-08-15       Impact factor: 49.962

2.  Homogeneously staining chromosomal regions contain amplified copies of an abundantly expressed cellular oncogene (c-myc) in malignant neuroendocrine cells from a human colon carcinoma.

Authors:  K Alitalo; M Schwab; C C Lin; H E Varmus; J M Bishop
Journal:  Proc Natl Acad Sci U S A       Date:  1983-03       Impact factor: 11.205

3.  Evidence for rearrangement, amplification, and expression of c-myc in a human glioblastoma.

Authors:  J Trent; P Meltzer; M Rosenblum; G Harsh; K Kinzler; R Mashal; A Feinberg; B Vogelstein
Journal:  Proc Natl Acad Sci U S A       Date:  1986-01       Impact factor: 11.205

4.  Correlation of basic fibroblast growth factor expression levels with the degree of malignancy and vascularity in human gliomas.

Authors:  J A Takahashi; M Fukumoto; K Igarashi; Y Oda; H Kikuchi; M Hatanaka
Journal:  J Neurosurg       Date:  1992-05       Impact factor: 5.115

5.  Molecular cloning and regulated expression of the human c-myc gene in Escherichia coli and Saccharomyces cerevisiae: comparison of the protein products.

Authors:  C Miyamoto; R Chizzonite; R Crowl; K Rupprecht; R Kramer; M Schaber; G Kumar; M Poonian; G Ju
Journal:  Proc Natl Acad Sci U S A       Date:  1985-11       Impact factor: 11.205

6.  Amino-terminal domains of c-myc and N-myc proteins mediate binding to the retinoblastoma gene product.

Authors:  A K Rustgi; N Dyson; R Bernards
Journal:  Nature       Date:  1991-08-08       Impact factor: 49.962

7.  Levels of c-myc oncogene mRNA are invariant throughout the cell cycle.

Authors:  C B Thompson; P B Challoner; P E Neiman; M Groudine
Journal:  Nature       Date:  1985 Mar 28-Apr 3       Impact factor: 49.962

8.  c-myc RNA degradation in growing and differentiating cells: possible alternate pathways.

Authors:  S G Swartwout; A J Kinniburgh
Journal:  Mol Cell Biol       Date:  1989-01       Impact factor: 4.272

9.  Immunohistochemical demonstration of DNA polymerase alpha in human brain-tumor cells.

Authors:  K Kunishio; N Mishima; T Matsuhisa; K Tsuno; N Matsumi; T Satoh; K Matsumoto; T Furuta; A Nishimoto; T Shiraishi
Journal:  J Neurosurg       Date:  1990-02       Impact factor: 5.115

10.  Metabolism of c-myc gene products: c-myc mRNA and protein expression in the cell cycle.

Authors:  P H Rabbitts; J V Watson; A Lamond; A Forster; M A Stinson; G Evan; W Fischer; E Atherton; R Sheppard; T H Rabbitts
Journal:  EMBO J       Date:  1985-08       Impact factor: 11.598

View more
  12 in total

1.  c-Myc proteolysis by the ubiquitin-proteasome pathway: stabilization of c-Myc in Burkitt's lymphoma cells.

Authors:  M A Gregory; S R Hann
Journal:  Mol Cell Biol       Date:  2000-04       Impact factor: 4.272

2.  Analysis of the c-myc IRES; a potential role for cell-type specific trans-acting factors and the nuclear compartment.

Authors:  M Stoneley; T Subkhankulova; J P Le Quesne; M J Coldwell; C L Jopling; G J Belsham; A E Willis
Journal:  Nucleic Acids Res       Date:  2000-02-01       Impact factor: 16.971

3.  Deletion mapping of gliomas suggest the presence of two small regions for candidate tumor-suppressor genes in a 17-cM interval on chromosome 10q.

Authors:  R Albarosa; B M Colombo; L Roz; I Magnani; B Pollo; N Cirenei; C Giani; A M Conti; S DiDonato; G Finocchiaro
Journal:  Am J Hum Genet       Date:  1996-06       Impact factor: 11.025

4.  c-Myc protein synthesis is initiated from the internal ribosome entry segment during apoptosis.

Authors:  M Stoneley; S A Chappell; C L Jopling; M Dickens; M MacFarlane; A E Willis
Journal:  Mol Cell Biol       Date:  2000-02       Impact factor: 4.272

Review 5.  Glucocorticoids, oxysterols, and cAMP with glucocorticoids each cause apoptosis of CEM cells and suppress c-myc.

Authors:  E B Thompson; R D Medh; F Zhou; S Ayala-Torres; N Ansari; W Zhang; B H Johnson
Journal:  J Steroid Biochem Mol Biol       Date:  1999 Apr-Jun       Impact factor: 4.292

6.  Proliferation and invasion: plasticity in tumor cells.

Authors:  Chong-Feng Gao; Qian Xie; Yan-Li Su; Julie Koeman; Sok Kean Khoo; Margaret Gustafson; Beatrice S Knudsen; Rick Hay; Nariyoshi Shinomiya; George F Vande Woude
Journal:  Proc Natl Acad Sci U S A       Date:  2005-07-15       Impact factor: 11.205

7.  Cell kinetic analysis in recurrent neuro-epithelial tumours.

Authors:  E Gömöri; I Mészáros; G Méhes; T Dóczi; L Pajor
Journal:  Acta Neurochir (Wien)       Date:  1996       Impact factor: 2.216

8.  ODZ1 allows glioblastoma to sustain invasiveness through a Myc-dependent transcriptional upregulation of RhoA.

Authors:  A Talamillo; L Grande; P Ruiz-Ontañon; C Velasquez; P Mollinedo; S Torices; P Sanchez-Gomez; A Aznar; A Esparis-Ogando; C Lopez-Lopez; C Lafita; M T Berciano; J A Montero; A Vazquez-Barquero; V Segura; N T Villagra; A Pandiella; M Lafarga; J Leon; J A Martinez-Climent; V Sanz-Moreno; J L Fernandez-Luna
Journal:  Oncogene       Date:  2016-09-19       Impact factor: 9.867

Review 9.  The Role of the Ubiquitin Proteasome System in Glioma: Analysis Emphasizing the Main Molecular Players and Therapeutic Strategies Identified in Glioblastoma Multiforme.

Authors:  Semer Maksoud
Journal:  Mol Neurobiol       Date:  2021-03-04       Impact factor: 5.682

10.  Glucocorticoid inhibition of 235-1 rat pituitary tumor cell cycle progression.

Authors:  Beverly C Delidow; Miranda Wang; Sonita V Bhamidipaty; Lynn D Black
Journal:  Endocrine       Date:  2002-03       Impact factor: 3.925

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.